Completed PHASE3 INTERVENTIONAL 2-arm NCT01142193

Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures

A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of USL255 as Adjunctive Therapy in Patients With Refractory Partial-Onset Seizures

Sponsor: Upsher-Smith Laboratories

Conditions Epilepsy

Interventions Placebo USL255

Updated 6 times since 2017 Last updated: May 19, 2014 Started: May 31, 2010 Primary completion: Dec 31, 2012 Completion: Jan 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Epilepsy and is currently completed. Upsher-Smith Laboratories leads this study, which shows 6 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

May 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Upsher-Smith Laboratories

Data source: Upsher-Smith Laboratories

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ashkelon, Israel , Athens, Greece , Auckland, New Zealand , Badalona, Spain , Bangalore, India , Barakaldo, Spain , Bedford Park, Australia , Boise, United States , Bonn, Germany , Bruges, Belgium and 59 more locations